David A. Siegel Viridian Therapeutics, Inc.\De Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Two Sigma Advisers, LP holds 304,400 shares of VRDN stock, worth $3.96 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
304,400
Previous 100,300
203.49%
Holding current value
$3.96 Million
Previous $2.18 Million
144.05%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
143Shares Held
62.1MCall Options Held
160KPut Options Held
354K-
Paradigm Biocapital Advisors LP New York, NY5.03MShares$65.5 Million3.3% of portfolio
-
State Street Corp Boston, MA4.49MShares$58.4 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$50.5 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.81MShares$49.6 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.66MShares$47.6 Million1.34% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $519M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...